A Phase I/II Study to Evaluate Single Agent and Combination Therapy With Megestrol Acetate and Dronabinol for the Treatment of HIV-Wasting Syndrome
Cachexia, HIV Infections, HIV Wasting Syndrome
About this trial
This is an interventional treatment trial for Cachexia focused on measuring Weight Loss, Megestrol, Cachexia, Eating Disorders, Tetrahydrocannabinol, Appetite
Eligibility Criteria
Inclusion Criteria Concurrent Medication: Allowed: Zidovudine (AZT), didanosine (ddI), and dideoxycytidine (ddC). If initiating new antiretroviral therapy, patient must have been on a stable dose for at least 4 weeks prior to study entry. Maintenance or suppressive therapy with any of the following, provided patient has been on a stable dose for at least 1 week prior to study entry: Ganciclovir or foscarnet for CMV retinitis. Fluconazole, amphotericin B, or flucytosine for cryptococcosis. Amphotericin B for disseminated histoplasmosis. Pyrimethamine, sulfadiazine, dapsone, or clindamycin for toxoplasmosis. Amikacin, clarithromycin, clofazimine, ethambutol, ciprofloxacin, or rifampin for disseminated Mycobacterium avium complex. Isoniazid, rifampin, ethambutol, or pyrazinamide for M. tuberculosis. Any of the following provided patient is on a stable dose for at least 1 week prior to study entry: Trimethoprim-sulfamethoxazole, aerosolized pentamidine, or dapsone for Pneumocystis carinii prophylaxis. Clotrimazole troches, nystatin suspension, ketoconazole, or fluconazole for oral candidiasis. Oral acyclovir for mucocutaneous herpes simplex. Narcotic analgesics, tranquilizers, sedative-hypnotics, or anticholinergic agents provided patient is on a stable dose for at least 1 week prior to study entry. Patients must have: HIV infection. HIV-wasting syndrome and anorexia. Life expectancy of at least 4 months. Ability to tolerate oral therapy, feed themselves, and have access to as much food as they desire with no dietary restrictions. Prior Medication: Allowed: Prior zidovudine (AZT), didanosine (ddI), and dideoxycytidine (ddC). Prior maintenance or suppressive therapy for certain opportunistic infections, as follows: Ganciclovir or foscarnet for CMV retinitis. Fluconazole, amphotericin B, or flucytosine for cryptococcosis. Amphotericin B for disseminated histoplasmosis. Pyrimethamine, sulfadiazine, dapsone, or clindamycin for toxoplasmosis. Amikacin, clarithromycin, clofazimine, ethambutol, ciprofloxacin, or rifampin for disseminated Mycobacterium avium complex. Isoniazid, rifampin, ethambutol, or pyrazinamide for M. tuberculosis. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: Major, acute opportunistic infections. Active neoplasms other than Kaposi's sarcoma or localized skin carcinoma. Diabetes, congestive heart failure, clinical ascites, or uncontrolled hypertension. Persistent grade 3/4 diarrhea. Impaired oral intake, such as occurs with Candida esophagitis or severe mouth ulcers. Clinically significant cardiac arrhythmias. Requirement for anticonvulsants for seizure disorder. Concurrent Medication: Excluded: Marijuana use. Anabolic steroids. Anticonvulsants for seizure disorders. Alcohol or barbiturates. Patients with the following prior conditions are excluded: Diagnosis of a major, acute opportunistic infection within 2 months prior to study entry. Hospitalization within 2 weeks prior to study entry. History of hypersensitivity reactions to megestrol acetate, dronabinol, or sesame oil (a component of the dronabinol capsules). History of thromboembolic events. History of psychiatric disorder other than depression. Prior Medication: Excluded: Prior dronabinol. Megestrol acetate within 2 months prior to study entry. Marijuana within 1 month prior to study entry. Anabolic steroids within 3 months prior to study entry. Current drug or alcohol abuse (patients with a history of occasional marijuana use are eligible provided they have abstained from its use for 1 month prior to study entry and agree to refrain from marijuana use for the study period).
Sites / Locations
- Denver Public Health Dept
- Univ of Illinois
- Univ of Kansas School of Medicine
- Tulane Univ Med School
- Univ of Maryland at Baltimore / Veterans Adm
- Washington Univ
- SUNY / Health Sciences Ctr at Brooklyn
- Portland Veterans Adm Med Ctr / Rsch & Education Grp
- Univ of Rhode Island / College of Pharmacy